Therefore, we demonstrate that targeting oncogenic genes such as EGFR in cancer cells treated with PARP inhibitors may potentially improve the therapeutic depth and duration of PARP-targeting therapies, which also fits into the exploration of targets in the DNA damage response (DDR) network for potential cancer therapeutic strategies. This evidence concerns the gene EGFR and cancer.